Faculty

Institution

Unit

Venue

William Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Pathology And Genomic Medicine

Department Of Pathology And Translational Molecular Pathology

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

William Fraser Symmans is a Professor at The University of Texas MD Anderson Cancer Center. His research focuses on breast cancer biology, neoadjuvant therapy response prediction, and the development of the Residual Cancer Burden (RCB) index for prognostic assessment. His recent work includes validating RCB in invasive lobular carcinoma, evaluating surrogate endpoints for survival in neoadjuvant trials, and investigating immune subtyping to identify hormone receptor-positive patients who benefit from immunotherapy, as demonstrated in the I-SPY2 trial analyses. He also contributes to pre-analytical standards for RNA sequencing from small biopsies. His publications appear in leading journals including the Journal of Clinical Oncology and Annals of Oncology, reflecting his influence on precision oncology and treatment optimization for early-stage breast cancer.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

William Fraser Symmans

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

breast cancer oncology cancer research cancer care cancer treatment medicinal research cancer biology radiation oncology breast oncology pharmacology clinical research medicine tumor biology pathology cancer genomics cancer imaging surgical oncology cancer management clinical trials molecular cancer oncogenes neoadjuvant chemotherapy cancer immunotherapy cancer genetics cancer cells anti-cancer agents cellular therapy tumor targeting cancer risk molecular diagnostics pharmacotherapy gynecologic oncology medical mycology leukemia cancer discovery endocrine oncology gene expression enzyme inhibition clinical evidence therapeutic efficacy prognosis drug targeting triple-negative breast cancer vascular biology breast surgery cancer prevention neoadjuvant therapy residual cancer burden microarray data analysis lymphoid neoplasia clinical radiation oncology breast imaging pathologic complete response cancer detection prognostic biomarkers drug trials novel therapies rna biology cytopathology clinical pathology neoadjuvant systemic therapy transcriptomics technology breast carcinoma breast cancer patients hematological malignancies cancer growth medical genetics ductal carcinoma preoperative chemotherapy clinical pharmacology tumor-infiltrating lymphocytes gene expression profiles phase ii study estrogen receptor neoadjuvant treatment inflammatory breast cancer

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1401: A Novel Statistical Framework for Surrogate Endpoint Prediction of Survival in Neoadjuvant Breast Cancer Trials.. Cancer Research (2026)

statisticsbreast cancerbreast oncologybiostatisticsoncologysurvival analysisprognosiscancer care

Pre-Analytical Best Practices for Rna Sequencing From Small Biopsies and Cytologic Specimens. Molecular Diagnosis & Therapy (2026)

geneticspathologygenomicsmolecular diagnosticslong-read sequencingnext-generation sequencinghigh throughput sequencingtranscriptomeomicscytologic specimensbiomedical analysissmall biopsiespre-analytical best practices

Adams Contribute to Triple Negative Breast Cancer via Mtorc1 Pathway: Targeting Adam-Mtor Axis Improves Efficacy. Cancer Letters (2025)

cancer biologymolecular cell biologymolecular cancerbreast cancercancer cellsoncogenesbreast oncologyadam-mtor axismtorc1 pathwaymolecular biologynegative breast cancertumor biologycell biologytherapeutic targets

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology (2025)

Otto Metzger FilhoKarla BallmanJordan CampbellMinetta LiuJennifer LigibelMark WatsonEveline ChenLili DuDaniel StoverLisa CareyAnn PartridgeJeffrey KirshnerHyman MussClifford HudisEric P. WinerLarry NortonW. Fraser Symmans

tumor targetingmedicinesurgical oncologycancer researchtumor biologyjama oncologytumor suppressorscancer treatmentbreast canceroncologypharmacotherapyimmunologycancer immunotherapyurologyoncogenesadjuvant dose-dense chemotherapytherapeutic efficacymedicinal researchnovel therapies

A Pooled Analysis Evaluating Prognostic Significance of Residual Cancer Burden in Invasive Lobular Breast Cancer. npj Breast Cancer (2025)

Rita A. MukhtarSoumya GottipatiChristina YauSara López-TarruellaHelena EarlLarry HaywardLouise HillerMarie OsdoitMarieke van der NoordaaDiane de CrozeAnne-Sophie HamyMarick LaéFabien ReyalGabe S. SonkeTessa G. SteenbruggenMaartje van SeijenJelle WesselingMiguel MartínMaria del Monte-MillánJudy C. BougheyMatthew P. GoetzTanya HoskinVicente ValeroStephen B. EdgeJean E. AbrahamJohn M. S. BartlettCarlos CaldasJanet DunnElena ProvenzanoStephen-John SammutJeremy S. ThomasAshley GrahamPeter HallLorna MackintoshFang FanAndrew K. GodwinKelsey SchwensenPriyanka SharmaAngela M. DeMicheleKimberly ColeLajos PusztaiMi-Ok KimLaura J van ’t VeerDavid CameronLaura J. EssermanW. Fraser Symmans

breast oncologybreast cancerbiostatisticscancer researchresidual cancer burdenprognostic significancepooled analysisprognostic evaluation

Aso Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-Spy2 Clinical Trial. Annals of Surgical Oncology (2025)

pathologybreast surgerycancer treatmentbreast cancerbreast oncologyneoadjuvant chemotherapyoncologyradiation oncologysurgical oncologyi-spy2 clinical trialradiologyaso visual abstractjama oncology

Aso Visual Abstract: Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-Spy 2 Clinical Trial. Annals of Surgical Oncology (2025)

clinical trialsbreast surgerybreast cancerbreast oncologycancer researchi-spy 2oncologyradiation oncologysurgical oncologybreast cancer outcomesradiologyaso visual abstractcancer caresurgery

Circulating Tumor Dna (Ctdna) in Patients With Stage 2/3 Hr+Her2-Negative Breast Cancer (Bc) Treated With Neoadjuvant Endocrine Therapy (Net) in the I-Spy2 Endocrine Optimization Pilot (Eop) Trial.. Journal of Clinical Oncology (2025)

Silver AlkhafajiMark Jesus M MagbanuaLaura van t VeerKarthik GiridharMatthew P. GoetzRita MukhtarChristos VaklavasAnthony D. EliasMei WeiGillian L. HirstHope S. RugoLaura Ann HuppertW. Fraser Fraser SymmansAlexander D. BorowskyLamorna Brown SwigartNatsuko OnishiDouglas YeeNola HyltonLaura EssermanJo Chien

geneticsneoadjuvant endocrine therapytumor dnabreast cancercancer researchoncologynovel therapiesendocrine-related cancers

Combination of Predicted Sensitivity to Endocrine Therapy (Set2,3 Index) and the Recurrence Score® in Node-Positive Breast Cancer: Independent Validation in the Pacs-01 Trial. European Journal of Cancer (2025)

cancer managementpredicted sensitivitybreast cancerbreast oncologybiostatisticscancer riskoncologycancer discoveryradiation oncologyset2,3 indexprognostic biomarkersendocrine-related cancerscancer caregynecologyrecurrence score®

Combined Prognostic Impact of Initial Clinical Stage and Residual Cancer Burden After Neoadjuvant Systemic Therapy in Triple-Negative and Her2-Positive Breast Cancer: An Analysis of the I-Spy2 Randomized Clinical Trial. Breast Cancer Research (2025)

pathologycancer treatmentbreast cancermedicinebreast oncologyoncologyradiation oncologysurgical oncologyher2-positive breast cancerinitial clinical stagecancer cellsresidual cancer burdencancer care

1
2
3
4
5
48
10 / page

William Fraser Symmans

Professor

The University of Texas MD Anderson Cancer Center

Affiliations

Department Of Breast Pathology

Department Of Pathology And Genomic Medicine

Department Of Pathology And Translational Molecular Pathology

Department Of Surgical Pathology

The University of Texas MD Anderson Cancer Center

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

William Fraser Symmans

The University of Texas MD Anderson Cancer Center

Professor

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 1401: A Novel Statistical Framework for Surrogate Endpoint Prediction of Survival in Neoadjuvant Breast Cancer Trials.. Cancer Research (2026)

statisticsbreast cancerbreast oncologybiostatisticsoncologysurvival analysisprognosiscancer care

Pre-Analytical Best Practices for Rna Sequencing From Small Biopsies and Cytologic Specimens. Molecular Diagnosis & Therapy (2026)

Adams Contribute to Triple Negative Breast Cancer via Mtorc1 Pathway: Targeting Adam-Mtor Axis Improves Efficacy. Cancer Letters (2025)

Adjuvant Dose-Dense Chemotherapy in Hormone Receptor–Positive Breast Cancer. Journal of Clinical Oncology (2025)

A Pooled Analysis Evaluating Prognostic Significance of Residual Cancer Burden in Invasive Lobular Breast Cancer. npj Breast Cancer (2025)

breast oncologybreast cancerbiostatisticscancer researchresidual cancer burdenprognostic significancepooled analysisprognostic evaluation

pathologybreast surgerycancer treatmentbreast cancerbreast oncologyneoadjuvant chemotherapyoncologyradiation oncologysurgical oncologyi-spy2 clinical trialradiologyaso visual abstractjama oncology

clinical trialsbreast surgerybreast cancerbreast oncologycancer researchi-spy 2oncologyradiation oncologysurgical oncologybreast cancer outcomesradiologyaso visual abstractcancer caresurgery

geneticsneoadjuvant endocrine therapytumor dnabreast cancercancer researchoncologynovel therapiesendocrine-related cancers

pathologycancer treatmentbreast cancermedicinebreast oncologyoncologyradiation oncologysurgical oncologyher2-positive breast cancerinitial clinical stagecancer cellsresidual cancer burdencancer care

1
2
3
4
5
48
10 / page